Rational Mutagenesis to Support Structure-Based Drug Design: MAPKAP Kinase 2 as a Case Study

2016 ◽  
pp. 308-331
Keyword(s):  
Drug Design ◽  
Support Structure ◽  
Structure Based Drug Design ◽  
Rational Mutagenesis

scholarly journals Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study

2009 ◽  
Vol 9 (1) ◽  
pp. 16 ◽  
Author(s):  
Maria A Argiriadi ◽  
Silvino Sousa ◽  
David Banach ◽  
Douglas Marcotte ◽  
Tao Xiang ◽  
...  
Keyword(s):  
Drug Design ◽  
Support Structure ◽  
Structure Based Drug Design ◽  
Rational Mutagenesis

scholarly journals An Overview of Computational Approaches in Structure Based Drug Design

1970 ◽  
Vol 2 (1) ◽  
pp. 53-61 ◽  
Author(s):  
Dipali Singh ◽  
Anushree Tripathi ◽  
Gautam Kumar
Keyword(s):  
Drug Design ◽  
Computer Aided Drug Design ◽  
Structure Based Drug Design ◽  
Computational Approaches ◽  
Ras Protein ◽  
Design Structure ◽  
Drug Lead ◽  
Computer Aided ◽  
Drug Designing

Drug design is a costly and difficult process. Drug must fulfill several criteria of being active, nontoxic and bioavailable. The conventional way of synthesizing drugs is a monotonous process. But computer aided drug design is a proficient way to overcome the tedious process of conventional method. Drugs can be designed computationally by structure or target based drug designing (SBDD). This review summarizes the methods of structure based drug design, usage of related softwares and a case study that explores to find a suitable drug (lead) molecule for the mutated state of H-Ras protein in order to prevent complex formation with Raf protein.Keywords: computer aided drug design; structure based drug design; Ras-proteinDOI: http://dx.doi.org/10.3126/njb.v2i1.5680Nepal Journal of Biotechnology Jan.2012, Vol.2(1): 53-61

Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor

MedChemComm ◽  
2013 ◽  
Vol 4 (1) ◽  
pp. 52-67 ◽  
Author(s):  
Stephen P. Andrews ◽  
Benjamin Tehan
Keyword(s):  
Parkinson’S Disease ◽  
Drug Design ◽  
G Protein ◽  
G Protein Coupled Receptors ◽  
Adenosine A2a Receptor ◽  
Structure Based Drug Design ◽  
A2a Receptor ◽  
Adenosine A2a ◽  
G Protein Coupled

The first example of structure-based drug design with stabilised GPCRs has enabled the identification of a preclinical candidate for the treatment of Parkinson's disease.

scholarly journals The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex

2016 ◽  
Vol 25 (6) ◽  
pp. 1096-1114 ◽  
Author(s):  
Orly Dym ◽  
Wanling Song ◽  
Clifford Felder ◽  
Esther Roth ◽  
Valery Shnyrov ◽  
...  
Keyword(s):  
Methylene Blue ◽  
Drug Design ◽  
Structure Based Drug Design ◽  
Crystallization Conditions ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document